[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616063":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":42,"centralContacts":54,"locations":63,"responsibleParty":80,"collaborators":12,"id":82,"slug":12,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":12,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":12,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":102,"overallStatus":66,"whyStopped":12,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Alexandria University","OTHER",[8,13,19,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","NO_INTERVENTION","Participants in this arm will receive standard supportive care for G-CSF-induced bone pain, but will not receive the study interventions (loratadine or diosmin-hesperidin).",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention","ACTIVE_COMPARATOR","Participants in this arm will receive loratadine 10mg tablets once daily, 30 minutes before filgrastim administration, for 5 days.",[18],"Drug: Loratadine",{"label":20,"type":21,"description":22,"interventionNames":23},"Diosmin-Hesperidin","EXPERIMENTAL","Participants in this arm will receive diosmin-hesperidin 500mg tablets twice daily, 30 minutes before filgrastim administration, for 5 days.",[24],"Drug: Diosmin-Hesperidin",{"label":26,"type":21,"description":27,"interventionNames":28},"Loratadine + Diosmin-Hesperidin","Participants in this arm will receive loratadine 10mg tablets once daily plus diosmin-hesperidin 500mg tablets twice daily, 30 minutes before filgrastim administration, for 5 days.",[29],"Drug: Loratadine + Diosmin-Hesperidin",[31,36,39],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":12},"DRUG","Loratadine","Loratadine 10 mg oral tablet administered once daily, starting 30 minutes before filgrastim administration and continued for 5 consecutive days.",[14],{"type":32,"name":20,"description":37,"armGroupLabels":38,"otherNames":12},"Diosmin-Hesperidin 500 mg oral tablet administered twice daily, starting 30 minutes before daily filgrastim administration and continued for 5 consecutive days.",[20],{"type":32,"name":26,"description":40,"armGroupLabels":41,"otherNames":12},"Combination of Loratadine 10 mg oral tablet once daily plus Diosmin-Hesperidin 500 mg oral tablet twice daily, starting 30 minutes before daily filgrastim administration and continued for 5 consecutive days.",[26],[43,46,48,50,52],{"name":44,"affiliation":5,"role":45},"Mai Moustafa Helmy, Professor","PRINCIPAL_INVESTIGATOR",{"name":47,"affiliation":5,"role":45},"Omar Mohamed Ghallab, Professor",{"name":49,"affiliation":5,"role":45},"Reham AbdelHalem Abo Elwafa, Professor",{"name":51,"affiliation":5,"role":45},"Noha Alaa Eldin Hamdy, Assistant professor",{"name":53,"affiliation":5,"role":45},"Mayssaa Mohamed Elsayed, pharmD",[55,60],{"name":56,"role":57,"phone":58,"phoneExt":12,"email":59},"Mayssaa Mohamed Elsayed, M.S. Candidate","CONTACT","+201097973834","Maya_salam2007@yahoo.com",{"name":61,"role":57,"phone":12,"phoneExt":12,"email":62},"Noha AlaaEldine Hamdy, Assistant professor","Noha.alaaeldine@alexu.edu.eg",[64],{"facility":65,"status":66,"city":67,"state":12,"zip":68,"country":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Alexandria University Hospitals","RECRUITING","Alexandria","21532","Egypt",{"type":71,"coordinates":72},"Point",[73,74],29.91582,31.20176,{"lat":74,"lon":73},[77],{"name":78,"role":57,"phone":79,"phoneExt":12,"email":59},"Mayssaa Mohamed Elsayed","+20 1097973834",{"type":81,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100616063",false,"NCT07300735","Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers","A Comparative Study of Diosmin-Hesperidin and Loratadine for the Prevention of G-CSF Induced Bone Pain in Patients With Hematological Malignancies","Inclusion Criteria:\n\n* Adults 18 to 65 years old\n* Receiving a G-CSF for one of the following indications:\n\nTreatment of neutropenia along with treatment for leukemia or lymphoma Neutropenia prevention following autologous hematopoietic cell transplant\n\n* Patients with or without bone pain associated with G-CSF administration.\n* Willingness to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with solid tumors.\n* Pregnant or breastfeeding women.\n* Patients with known allergies or hypersensitivity to Loratadine, Diosmin- Hespiridin or Filgrastim.\n* Patients with pre-existing bone disorders or receiving bone modifying agents\n* Chronic use of antihistamines, Diosmin-Hespiridin, NSAIDs, corticosteroids, or immunosuppressants.\n* Receiving medications with drug interaction grade X with Loratadine, Diosmin-Hespiridin or Filgrastim\n* Patients who are unable to understand or provide informed consent","ALL","18 Years","65 Years",{"count":92,"type":93},88,"ESTIMATED","INTERVENTIONAL",[96],"NA","This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain.\n\nThe study is comparing two oral medications for their effectiveness as a preventive treatment:\n\n* Diosmin-Hesperidin (a flavonoid supplement).\n* Loratadine (a common anti-allergy medication).\n\nThe core question the study is trying to answer is:\n\n* Is diosmin-hesperidin effective in preventing G-CSF-induced bone pain compared to loratadine?\n* Does the combination of diosmin-hesperidin and loratadine offer better pain prevention than either drug alone?",[99,100,101],"Hematologic Malignancy","Neutropenia","Bone Pain",[33,103,104,105,106,107,108,109,110,111],"Diosmin","Filgrastim","Granulocyte Colony Stimulating Factor","G-CSF Induced Bone Pain","Hesperidin","Flavonoid","Antihistamine","Prophylaxis","Randomized Controlled Trial","2026-06-23",{"date":114,"type":115},"2026-06-24","ACTUAL",{"date":117,"type":115},"2025-03-01",{"date":119,"type":93},"2027-07",{"name":5,"class":6},1]